Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity.
Juana Carretero GómezJavier EnaJosé Miguel Seguí RipollFrancisco Javier Carrasco SánchezRicardo Gómez HuelgasJosé Manuel Casas RojoManuel Suárez TembraJuan Jesús Carabantes RuedaJosé Carlos Arévalo-LoridoPublished in: Current medical research and opinion (2021)
Our results show a beneficial effect of the combination of GLP-1RAs plus SGLT2is on liver steatosis that goes beyond glucose control, and it is related mainly to weight loss, a decline in biomarkers and reductions in abdominal circumference. For many patients, early detection is essential to improving outcomes in NAFLD and could allow us to select the most efficient treatment options.
Keyphrases
- weight loss
- insulin resistance
- high fat diet induced
- end stage renal disease
- ejection fraction
- high fat diet
- bariatric surgery
- chronic kidney disease
- newly diagnosed
- metabolic syndrome
- body mass index
- type diabetes
- roux en y gastric bypass
- prognostic factors
- peritoneal dialysis
- gastric bypass
- blood pressure
- blood glucose
- patient reported outcomes
- glycemic control
- patient reported